National Medicines Management Programme

Michael Barry

28th November 2013

The Medicines Management Programme

Multi-disciplinary Medicines Management Programme (MMP) headed by the National Medicines Information Centre (NMIC) and the National Centre for Pharmacoeconomics (NCPE) in collaboration with the HSE-Primary Care Reimbursement Service (PCRS)

Providing sustained national leadership relating to
- Safe
- Effective
- Cost–effective prescribing
Following cost containment measures drug expenditure fell to just over €1.8 billion in 2011 but forecasts indicate that spending on drugs under the Community Drugs schemes could exceed €2 billion in 2013.

Against this background it is essential to ensure that prescribing of medicines is safe, effective and cost-effective.

HSE - Medicines Management Programme

(HSE - MMP)

Key areas of focus for the MMP

- ACE inhibitors
- ARBs
- Proton Pump Inhibitors (PPI's)
- Statins
- Generic Prescribing
- New oral anticoagulants
- Pregabalin
- Reference pricing
- New high cost drugs
The MMP ‘preferred drug’ initiative

Factors considered in making a recommendation for a ‘preferred drug’

- range of therapeutic indication(s)
- clinical evidence base
- clinical guidelines (National & International)
- cost
- patient related factors
- current prescribing practice

ACE inhibitors & ARBs
ACE inhibitors

Over 130,000 prescription items are issued each month for ACE inhibitors and expenditure on this class of drugs exceeds €14.7 million per annum. Prescribing trends are as follows:

ACE inhibitors (85% of all ACE items) - 53% ramipril (average cost/item = €4.80)
28% perindopril (average cost/item = €11.26)
12% lisinopril (average cost/item = €4.78)
2.6% enalapril, 2.3% captopril, 1.5% quinapril

ACE + diuretic (11.4% of all ACE items)
ACE + Calcium antagonist (3.6% of all ACE items)

Ramipril has a wide range of therapeutic indications including the following:

1. Hypertension
2. Heart failure
3. Cardiovascular risk reduction – in patients with CHD, CVA, PVD & Diabetes Mellitus
4. Treatment of renal disease – glomerular diabetic (and non diabetic) nephropathy

We believe ramipril is the ACE inhibitor of choice

Making ramipril the ACE of choice could result in savings in excess of €2 million/annum

ARBs

Over 115,000 prescription items are issued each month for ARBs and expenditure on this class of drugs exceeds €24.5 million per annum. Prescribing trends are as follows:

ARBs alone (66% of all ARB items) - 27% valsartan (average cost/item = €11.90)
22% losartan (average cost/item = €13.65)
18% telmisartan (average cost/item = €17.85)
16% olmesartan (average cost/item = €16.86)
10% candesartan (average cost/item = €12.51)
5% irbesartan (€15.27), 2% eprosartan (€17.89)

ARB + diuretic (32% of all ARB items)
ARB + Calcium antagonist (2% of all ARB items)

Only 3 ARBs are indicated for hypertension & heart failure i.e. candesartan, losartan & valsartan. When used for the treatment of heart failure valsartan should be administered twice daily with the clinical trial evidence base suggesting 160 mg twice daily. The GMS prescribing database indicates that <1% of all patients treated with valsartan receive the twice daily dose (€29.86)

We believe candesartan is the ARB of choice

Making candesartan the ARB of choice could result in savings in excess of €2.3 million/annum
So remember:

Statins: Think **SIMVASTATIN**
PPI: Think **LANSOPRAZOLE**
ACE inhibitor: Think **RAMIPRIL**
ARB: Think **CANDESARTAN**

The MMP ‘preferred drug’ initiative

North Western Health Board Region:
- **RAMIPRIL** as % of all ACE inhibitors = 60%
- **CANDESARTAN** as % of all ARBs = 8%
- **LANSOPRAZOLE** as % of all PPIs = 30%
- **SIMVASTATIN** as % of all Statins = 10%

National & Regional Prescribing Rates of Preferred Drugs – example NWHB

National Prescribing Rates:
- **RAMIPRIL** as % of all ACE inhibitors = 53%
- **CANDESARTAN** as % of all ARBs = 10%
- **LANSOPRAZOLE** as % of all PPIs = 23%
- **SIMVASTATIN** as % of all Statins = 0%
Next steps for the ‘preferred drug’ initiative

Reference pricing and the MMP

Reference pricing begins with the IMB identifying ‘interchangeable drugs’. Atorvastatin (Lipitor) was the first drug and will be followed by esomeprazole (Nexium), rosuvastatin (Crestor) with omeprazole (Losec Mups) and pravastatin (Lipostat) later. It is envisaged that 20 drugs will be identified as interchangeable by May 2014.

In setting the reference price the following criteria are considered:

1. The ability of suppliers to meet patient demand
2. Value for money afforded by the relevant listed items
3. Equivalent relevant prices in other Member States (EU 28).
4. The relevant prices of therapeutically similar listed items e.g. simvastatin for atorvastatin
5. Resources available to the Executive
6. The terms of any agreements in place with stakeholders e.g. IPHA
Generic Prescribing

Generic prescribing rate – PPIs = 24% - 69%
- Statins = 36% - 71%

Percentage of prescriptions dispensed generically under the GMS Scheme in 2005 and 2012

2005 2012
- Generic 4.0% 50%
- Branding Generic 19.5% 25.5%
- Proprietary non-generic 24.5% 25.5%
- Proprietary originator generic
**New oral anticoagulants**

**Reimbursement approval for new Anticoagulant**

Over 70% of NOAC prescribing is for patients ≥ 70 years

70-74 years = 17.53%
75 + years = 52.51%

Atrial fibrillation accounts for 86.9% of all applications for NOACs
The new Reimbursement Approval form for NOACs – enhancing safety

The new reimbursement approval form will include information in relation to the following:

- CHADS² Score
- CHA²DS² - VASc Score
- HAS - BLED Score
- Cockcroft-Gault Eqn for GFR (ml/min)

Current prescribing of oral anticoagulants – expenditure

Growth in NOAC utilisation and expenditure is, in part, related to the issue of INR monitoring in the primary care setting.

Over 60% of NOAC prescribing takes place in the South and West of the Country.

Which NOAC for AF?
Bayesian mixed treatment comparison (MTC) underway
The Medicines Management Programme

Under the Medicines Management Programme there is an increased emphasis in obtaining utilisation and expenditure data under the Community Drugs Schemes.

HTA is considered part of MMP and may be used where there is concern in relation to value for money.

Examples of HTAs carried out under the MMP include:
- Omacor
- Pregabalin (Lyrica)

The Medicines Management Programme

An important component of the MMP is communication with our prescribing colleagues. The NMIC has a 20 year record in such communications including our publications ‘NMIC Bulletin’ and ‘Therapeutics Today’.

Under the MMP we are now conducting a series of GP meetings around the country with the support of the ICGP and the RCPI. Meetings to date:
- Dublin x 2
- Dun Laoghaire
- Waterford
- Killarney
- Donegal

Next meetings will be held in Kildare, Dublin, Cork and Galway.

In 2014 we aim to communicate with GPs through our Pharmacy Advisors.
Thank you